.png){kind=icon}
.png){kind=icon}
Return
In Vitro Metabolism of Δ8-, Δ9-, and Δ10-THC in Human Hepatocytes: Distinct Δ10-THC Biotransformation and Implications for Drug Testing
.png){kind=icon}
OA
AI
R
H
M
F
M
DOI：10.1002/dta.70101.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
With its widespread recreational and increasing medical use, ∆9-tetrahydrocannabinol (∆9-THC), the main psychoactive compound in cannabis, is regularly subjected to drug testing in clinical and forensic toxicology. ∆8- and ∆10-THC have recently entered unregulated drug markets. Their close structural similarity to ∆9-THC poses various analytical challenges, with a high risk of misidentification and misinterpretation of bioanalytical data. This study investigated the in vitro metabolic fate of ∆8- and ∆10-THC in comparison to ∆9-THC using human hepatocytes and high-performance liquid chromatography coupled to high-resolution time-of-flight analysis (HPLC-QToF). A comparable metabolism was observed for ∆8-THC and ∆9-THC, with the formation of the monohydroxy and carboxy metabolites and their glucuronides. In contrast, ∆10-THC was found to be extensively glucuronidated (forming ∆10-THC-glucuronide) and monohydroxylated, with only minor formation of a carboxy metabolite. Structural considerations led to the hypothesis that ∆10-THC is predominantly hydroxylated at a different site than ∆8-THC and ∆9-THC. THC isomers should be considered in cannabis drug testing. The differing metabolism of ∆10-THC exacerbates the risk of misinterpretation of analytical results.
Keywords:
cannabis
forensic toxicology
metabolism
semi-synthetic cannabinoids
SSC
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
D
IF:
2.7
Papers:
127
Citations:
0
Organization
Cited Papers